chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt was given covid Pfizer vaccine.  Pt c/o lightheadedness apptroxximately 10 minutes after shot.  Vitals were taken and wnl.  Pt was given crackers and juice and had relief.  Pt stated a little dizziness, but better.
Patient administered vaccine on 1/14/21 with no reactions noted after 15 minutes. Patient seen for wellness visit on 1/20/21 with no complaints regarding vaccine. Patient died on 1/30/21
Pt experienced chickenpox. Pt had a fever of 101.8 for two days and had a fever for four days total. Pt had 40 spots mostly on chest and back.  Pt was treated with Amoxicillin trihydrate, Augmentin, and Zithromax.
Information has been received on 28-JUN-2017 from an office manager via a company representative regarding a 1 year old patient of unknown gender. The patient's concurrent conditions, medical history and concomitant medications were unknown. On either 27-JUN-2017 or 28-JUN-2017, the patient received both VARIVAX (lot number and expiration unknown) subcutaneous for prophylaxis and PROQUAD (lot number and expiration unknown) subcutaneous for prophylaxis. The reporter stated the patient received a "double dose of varicella" on either 27-JUN-2017 or 28-JUN-2017. So far, the patient has not experienced any adverse effects from this. As of 28-JUN-2017, it is unknown if the patient will continue to receive the VARIVAX or PROQUAD and the outcome of receiving both vaccines was unknown. Follow-up information was received on 30-JUN-2017 from an office manager. On 27-JUN-2017 the patient received both VARIVAX (lot number M041513 and expiration date 11-OCT-2018) and PROQUAD (lot number M037010 and expiration date 21-FEB-2018). No adverse effects reported. No further information was provided. Follow-up information was received on 03-JUL-2017,  from  a physician via an office manager. It was reported  that the patient was vaccinated on 27-JUN-2017, and a properly stored sterile diluent (DILUENT MRK) was used to reconstituted both VARIVAX (lot number M041513 and expiration date 11-OCT-2018) and PROQUAD (lot number M037010 and expiration date 21-FEB-2018). An on unspecified date in 2017, the patient experienced an adverse event (unspecified details). The patient's outcome for adverse event was unknown.
I developed a sinuses infection that won't go away, then I realized I had a rash on my forehead and the doctor said I had sinus infection and shingles. He prescribed me AUGMENTIN antibiotic, I started to feel better after 14 days. It got worse before it got better.
Initial misuse report received from a healthcare professional on 03 September 2013. This is an invalid case as individual patient identifiers are not reported. Some patient (No information was provided regarding the patient) had received expired dose of ACTHIB vaccine. No adverse event was reported. List of documents held by sender: none.
As I was administering the vaccine I was discussing with the patient the adverse reactions I wanted to monitor after the injection. The patient winced as the vaccine was being injected and said it was more painful than the last time he go it. He immediately stated he didn't feel well. I applied a little pressure to the injection site which he said made it feel better but he was starting to feel flushed and faint. I kept the patient in the chair and got him some water. He reported that he had experienced this before with vaccines but it had been a long time. He asked to lay on the floor so we got him into a prone position on the floor on his right side. He laid there for a few minutes then drank some more water and laid back down. After a few more minutes he was ready to sit up. He moved to a chair in our waiting area left when he felt well enough. I called patient 2 hours later to check on himand he reports he is doing fine.
Patient is unable to lift her left arm above her elbow.  She cannot lay on it and hasn't since the administered date. Hasn't seeked medical attention yet.
This spontaneous report was received from a female pharmacist of unknown age via company representative reporting on herself. The patient's medical history was not reported. Concomitant therapies included sterile diluent (STERILE DILUENT). On 15-JUN-2017, when the pharmacist administered a dose of ZOSTAVAX (anatomical location, lot# and expiration date were not reported) for prophylaxis , "some of the vaccine got into her eye"exposure via eye contact ).  The pharmacist stated "the needle did not touch her eye and she flushed her eye out with water". No treatment was given. There was no product quality complaint (PQC) involved.
Pt recvd measles vax on 11JAN91 & on 19MAR91 pt had a pos pregnancy test; LMP 20FEB91; pt exp some spotting which resolved & quantitative HCG levels cont to rise; On 12APR91 pt pregnancy was terminated;
The pt had increased temperature on 12/6/01 with vomiting, hematuria, petechiae around his mouth, a generalized rash and blanches to touch. Treated with Phenergan rectal suppository for vomiting and Pediapred 5cc po q d X 5 days.
Noted yesterday to develop "itching, quarter to nickel size raised, red areas" on top of back thighs area, right mid back and right wrist.  Instructed her to notify her physician.  No other complaints.
got the shots, it made the other times much easier / suspected vaccination failure; other times much easier; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a 77-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had Shingles 2.5 years ago) and pregnancy (had four children with natural birth).   On an unknown date, the patient received the 1st dose of Shingles vaccine and the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional case details were reported as follows: The reporter was patient itself. The age at vaccination was not reported. The reporter stated if you had suffered like how she did  or do you would feel differently. The patient had shingles 2.5 years before day of reporting. It was so bad she could not walk. She had four children with natural birth and the pain combined did not exceed the pain of Shingles.  The patient had never hurt so bad from anything in my 77 years. Unfortunately, had the aftermath of Shingles, meaning she would have this pain the rest of her life. Her side and back hurts to touch. She could not even wear the clothes she want to wear because she could not stand for her clothes to touch her skin. The patient suggested to get the shots. Her family did after seeing she suffer. The patient got the shots after my first attack and it made the other times much easier. The patient not selling but trying to save others from pain. This case was considered as suspected vaccination failure, as details regarding laboratory test confirmation and time to onset for shingles were unknown at the time of reporting. The follow up was not required.
Information has been received from a nurse practitioner (NP) concerning an 18 year old female who on 31-MAY-2007 was vaccinated with Gardasil (LOT # 657736/0389U). Concomitant therapy included a cough expectorant (unspecified), which was taken on the same morning. On 31-MAY-2007, the patient went out to the reception area after she received her second Gardasil, and began "shaking and fell down". The NP reported that she thought that the patient had experienced "a short seizure that lasted about 15 seconds". The NP also reported that the patient had three red streaks running down her arm from the injection site area and that the patient stated she felt a rush down her arm at the time she was vaccinated. The patient's blood pressure was "a little low" and her lips were pale. The patient was sent to an urgent care facility to be further evaluated. The nurse indicated that the patient did not have a reaction to the first dose of Gardasil. Upon internal review, seizure was determined to be an other important medical event. Additional information has been requested.
Rash on both arms, neck, and chest. Itchy. Lasted for 2 days. Went away without treatment.
This spontaneous report as received from a pharmacist refers to a 45 years old patient. On 14-MAY-2014 the 45 years old patient was vaccinated with ZOSTAVAX, 0.65 ml (lot# and route were unknown). No adverse effects reported. Additional information has been requested.
Large red area around injection site. Skin warm to touch. Pt states feeling achy over body.
Profuse nose bleed 4 days after first vaccination; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 10Apr2021 at 09:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included two and half parathyroid glands removed in 2015 with no cancer involvement. Concomitant medications included calcium (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) taken for unknown indication from unknown date and unknown if ongoing. The patient previously received codeine (MANAFACTURER UNKNOWN) on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 11:15, the patient experienced profuse nose bleed four days after the first vaccination. This occurred while bending over looking in refrigerator. This was not common and the patient never had a nose bleed like that before. This took approximately 20 minutes to stop and the patient was wondering  if this was possibly related to her vaccination or if this had occurred with other patients. It was reported that she was recovering but if it recurred she might need an additional assistance. The event did not result in doctor/other health care professional office/ clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event profuse nose bleed 4 days after first vaccination was recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Pt accompanied by parent// Pediatric pt was inadvertently given an adult dose (PFIZER Lot  FJ8762). Adult parents were being vaccinated at same table as pediatric pts. Two pediatric doses and two adult doses were placed on the table, and the two adult doses were inadvertently used for the pediatric vaccinations. Process of vaccination was without incidence. After vaccination mistake the Medical Evaluator and DOH personnel on site were notified. Parents were notified shortly thereafter by the Medical Evaluator and vaccinator. Medical Evaluator gave parents instructions for monitoring health outcomes for the pediatric pts and contacting their pediatrician if necessary. All parent questions were answered. Pt stayed for a longer period of time in observation due to parents' vaccination. No adverse reaction was observed during the waiting time, approx 30 min.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Oct2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 67 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.   Clinical course: The patient received COVID 19 treatment with Paxlovid from 19Dec2022 to 23Dec2022.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Pt recvd a dose of Engerix-B between MAY92 & JUN92; pts devel rash, pruritus & pain @ inject site; most p/receiving the 1st dose;
Client reported chest pressure rated 1/10 in quality at 3:53PM. EMS was called. Client reported that the pressure went away and did not leave with EMS. Denied difficulty breathing, blurred vision.Vital signs BP 116/75, O2 98%, HR 88, T 98.3 F. Client advised to call EMS if symptoms of chest pressure or difficulty breathing return. She verbalized understanding.
The area surrounding the vaccine site (3 inch diameter circle) was red.  It was not warm or anything else.  She stated she woke up with this on 10/13/22 and it was still there when she came into the pharmacy today (10/14/22)
Developed red, swollen area around injection site, approximately 3?X3?. Site is warm to touch and per patient is ?itchy?. Denies any pain, muscle aches, fever or headache.
This spontaneous report as received from registered nurse via company representative refers to a female patient of unknown age. The patient's medical history and current condition are not reported. On 13-AUG-2014 the patient was vaccinated with ZOSTAVAX (lot # and expiry date not provided) of unknown strength and dose. Other co-suspects and concomitant medication are not reported. On an unknown date the patient experienced several blisters around the injection site and had an itchy arm after receiving ZOSTAVAX shot. Cancer, overdose and product quality complaint was not reported. The outcome of the events was reported as not recovered. Causality was unspecified by the reporter. Additional information has been requested.
Pts. left arm has 4"x1" erythema, 3"x2.5" swelling warm and painful site. Iced several times and took 25mg of BENADRYL.
Diarrhea; Confused; Dizziness; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), DIZZINESS (Dizziness) and NAUSEA (Nausea) in an 85-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, the patient experienced DIARRHOEA (Diarrhea), DIZZINESS (Dizziness) and NAUSEA (Nausea). At the time of the report, DIARRHOEA (Diarrhea), DIZZINESS (Dizziness) and NAUSEA (Nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. The treatment medication was Tylenol.   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: TCR / Outcome updated
Fever 102 Chills Headache Extreme Fatigue Nausea Weakness Arm pain at site
Approximately 30 minutes after receiving the vaccination, patient reports itching started on left arm, then the head, then both arms and then lower back.  No redness, erythema, or hives.  Itching progressed  to the ears and throat started to feel "sticky/funny" within 1 hour of receiving the vaccine.  Diphenhydramine 50 mg and Famotidine 20 mg administered.  Itchiness resolved 15 to 30 minutes after receiving diphenhydramine and famotidine.  However, lips and tongue feel "tingly".
Temporary numbness between wrist and shoulder of left arm; Temporary loss of function in left arm; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Temporary numbness between wrist and shoulder of left arm) and LIMB DISCOMFORT (Temporary loss of function in left arm) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Rheumatoid arthritis (Gradual improvement.) since 1996 and Hypertension since 2018. Concomitant products included HYDROXYCHLOROQUINE and ASPIRIN [ACETYLSALICYLIC ACID] for Arthritis, METOPROLOL for Hypertension, METHOTREXATE and HYDROXYCHLOROQUINE SULFATE (PLAQUENIL [HYDROXYCHLOROQUINE SULFATE]) for Rheumatoid arthritis.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced HYPOAESTHESIA (Temporary numbness between wrist and shoulder of left arm) and LIMB DISCOMFORT (Temporary loss of function in left arm). On 11-Apr-2021, HYPOAESTHESIA (Temporary numbness between wrist and shoulder of left arm) and LIMB DISCOMFORT (Temporary loss of function in left arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were provided   This case was linked to MOD-2021-266384 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Follow up received  on 24-jul-2021. No New Information. On 25-Jul-2021: Significant Follow up received on 26-Jul-2021.Patient medical history updated, concomitant medications, 2nd dose events updated.
It might be close to 10 weeks before they get their 2nd dose; No adverse event; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (It might be close to 10 weeks before they get their 2nd dose) and NO ADVERSE EVENT (No adverse event) in a 2-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    In July 2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (It might be close to 10 weeks before they get their 2nd dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (It might be close to 10 weeks before they get their 2nd dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            No concomitant medications were reported.  Two years old patient received their 1st dose of Moderna Covid-19 vaccine at the end of July 2022. It might be close to 10 weeks before they get their 2nd dose.They could not get it sooner, because of their schedule.  No treatment medications were reported.   Reporter did not allow further contact
I had a respiratory cough, since two weeks after shot. It is now almost 5 months later and cough (bronchitis) is still present. Wondering if the vaccine shot lessened my ability to recover. I have taken prescription cough syrup, nasal sprays, and finally an antibiotic; nothing has worked. I am under the care of a pulmonologist.
COVID-19 Positive after the first dose; This spontaneous case was reported by a nurse and describes the occurrence of COVID-19 (COVID-19 Positive after the first dose) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. UNK) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, the patient experienced COVID-19 (COVID-19 Positive after the first dose). At the time of the report, COVID-19 (COVID-19 Positive after the first dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-May-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that patient was around 50-years of age.  No concomitant medications reported.  Treatment of the events were not reported.  It was reported that the patient was scheduled for the second dose on 22-MAY-2021.
Sore arm into armpit; Rash on chest; Sleepiness; Muscle ache; Joint aches; Sore arm; Headache; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CW0173) via an unspecified route of administration in the left arm on 30Apr2021 at 09:15 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergy, depression and anaemia. The patient had known allergies to latex and melon. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included bupropion (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN), armodafinil (MANUFACTURER UNKNOWN) and fluticasone (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 02Apr2021 at 09:15 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Apr2021 at 12:00, the patient experienced sleepiness, muscle ache, joint aches, sore arm and headache. On 01May2021, the patient experienced the same events. On 02May2021, the patient experienced sleepiness, sore arm into armpit and rash on chest. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sleepiness, muscle ache, joint aches, sore arm, headache, sore arm into armpit and rash on chest was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Moderately large local reaction over left deltoid with redness across area where IPV administered. Pt complained of itching. Viewed by pediatrician. Advised Benadryl, cool compress.
Mother arrived with 2 children for 2nd dose of Pfizer vaccine.  Both children received Pfizer Pediatric vaccine. Patient is 12 and should have received Pfizer vaccine for 12 and older. (Patient received Pfizer for 12 and older for 1st vaccine.) Mistake noticed immediately.  On-site physician consulted and advised to provide an additional 20mcg of Pfizer Pediatric dose to equal 30 mcg adult dose. Mother consulted and offered to not re-vaccinate or provide the additional dose and both mother and daughter chose to receive additional dose.
No period for 6-8 months, then brutal period for 1 month. I had a biopsy of the uterine lining that came back positive for endometrial hyperplasia.
Several small red dots (likely petechiae) on and surrounding injection site, no inflamation, significantly delayed appearance.